Benitec Biopharma Inc.

NasdaqCM:BNTC Stock Report

Market Cap: US$268.8m

Benitec Biopharma Future Growth

Future criteria checks 0/6

Benitec Biopharma is forecast to grow earnings and revenue by 23.2% and 74.7% per annum respectively while EPS is expected to grow by 19.9% per annum.

Key information

23.2%

Earnings growth rate

19.9%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate74.7%
Future return on equityn/a
Analyst coverage

Good

Last updated16 Dec 2024

Recent future growth updates

No updates

Recent updates

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Oct 02
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Benitec Biopharma prices of $18M securities offering

Sep 13

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Sep 02

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

Jan 13
We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Sep 30
We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

May 12
Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

Benitec Bio secures $13M capital via equity offering

Apr 28

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

Jan 27
Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Dec 02
How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Earnings and Revenue Growth Forecasts

NasdaqCM:BNTC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2027N/A-61-10N/A5
6/30/2026N/A-43-21N/A6
6/30/2025N/A-32-36-247
9/30/2024N/A-21-20-19N/A
6/30/2024N/A-22-20-19N/A
3/31/20240-22-20-20N/A
12/31/20230-22-18-18N/A
9/30/20230-21-19-19N/A
6/30/20230-20-18-18N/A
3/31/20230-20-19-19N/A
12/31/20220-19-18-18N/A
9/30/20220-18-16-16N/A
6/30/20220-18-16-16N/A
3/31/20220-17-16-16N/A
12/31/20210-18-15-15N/A
9/30/20210-16-15-15N/A
6/30/20210-14-13-13N/A
3/31/20210-13-11-11N/A
12/31/20200-11-10-10N/A
9/30/20200-10-10-9N/A
6/30/20200-8-8-8N/A
3/31/20201-7-6-6N/A
12/31/20191-6N/AN/AN/A
9/30/20197-222N/A
6/30/201912345N/A
3/31/201912244N/A
12/31/2018122N/AN/AN/A
9/30/20188-3-3-3N/A
6/30/20183-9N/A-7N/A
3/31/20184-9N/A-7N/A
12/31/20176-7N/A-5N/A
9/30/20175-7N/A-5N/A
6/30/20179-4N/A-6N/A
3/31/20177-7N/A-6N/A
12/31/20167-8N/A-10N/A
9/30/20167-12N/A-13N/A
6/30/20163-18N/A-15N/A
3/31/20163-18N/A-17N/A
12/31/20152-16N/A-14N/A
9/30/20152-12N/A-10N/A
6/30/20153-9N/A-7N/A
3/31/20153-6N/A-5N/A
12/31/20141-7N/A-7N/A
9/30/20141-7N/A-8N/A
6/30/20141-7N/A-9N/A
3/31/20141-5N/A-8N/A
12/31/20131-3N/A-6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BNTC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BNTC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BNTC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BNTC is forecast to have no revenue next year.

High Growth Revenue: BNTC is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BNTC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 05:17
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Benitec Biopharma Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Debjit ChattopadhyayGuggenheim Securities, LLC
Raghuram SelvarajuH.C. Wainwright & Co.